Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions

References

Page 1

	Year	Citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) E. Eisenhauer, P. Therasse, Jan Bogaerts, European Journal of Cancer Surgical OncologyRecist GuidelineMedicineCancer ManagementSolid Tumours	2008	28.6K
Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases Timothy M. Pawlik, Charles R. Scoggins, Daria Zorzi, Annals of Surgery	2005	1.1K
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases Kyle E. Rusthoven, Brian D. Kavanagh, Stuart H. Burri, Journal of Clinical Oncology	2009	1.1K
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial Theo J. M. Ruers, Frits van Coevorden, Cornelis J.A. Punt, JNCI Journal of the National Cancer Institute	2017	657
Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure? René Adam, Dennis A. Wicherts, Robbert J. de Haas, Journal of Clinical Oncology	2009	575
Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases Mark Lee, John J. Kim, Robert Dinniwell, Journal of Clinical Oncology	2009	476
An Overview of Hypofractionation and Introduction to This Issue of Seminars in Radiation Oncology Robert Timmerman Seminars in Radiation Oncology Radiation MedicineMedical ImagingRadiation TherapyMicroscopyRadiation Therapy Planning	2008	473
Phase II study on stereotactic body radiotherapy of colorectal metastases Henrik Roed, Anders Traberg Hansen, Lars Ohlhuis, Acta Oncologica	2006	421
Stereotactic body radiotherapy for colorectal liver metastases Daniel T. Chang, Anand Swaminath, Margaret M. Kozak, Cancer	2011	296
Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial Xin Shelley Wang, Laurence D. Rhines, Almon S. Shiu, The Lancet Oncology	2012	295

Page 1